© 2023. All Rights Reserved. 

# Virena SARS-CoV-2 Mapping and Positivity




In connection with the questions we have received regarding prevalence of COVID, we are providing recent data showing SARS-CoV-2 mapping and positivity by state recorded through our proprietary Virena platform.

As a result of this positivity, we are increasing our manufacturing of COVID assays to a level that we believe prudent, but we are not changing our view that our annual COVID-19 revenue is expected to be $300 million to $400 million now that we are entering the endemic state.




*The above contains forward-looking statements, which represent management's judgment and expectations as of today. Forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, those factors identified under "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 23, 2023 and subsequent reports filed with the SEC. Except as required by law, we undertake no obligation to update any forward-looking statement or any time-sensitive information to reflect future events, developments or changed circumstances, or for any other reason.*